依托成熟毒素平台百利天恒BL-M05D1胃癌III期试验完成首例入组

财中社06-04 19:52

　　6月4日，百利天恒（688506）发布公告，公司自主研发的创新生物药注射用BL-M05D1（Claudin18.2ADC）用于在既往经一线治疗的Claudin18.2阳性晚期胃癌或胃食管结合部腺癌的III期临床试验已完成首例受试者入组。

　　注射用BL-M05D1是与iza-bren共享同一“连接子+毒素”平台的ADC药物，目前正在国内外开展3项临床试验，其中包括1个III期、1个Ib期及1个Ia期临床试验，适应症为局部晚期实体瘤。

　　2026年一季度，百利天恒实现收入9459万元，归母净利润-7.75亿元。

（文章来源：财中社）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2640197152?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-04 19:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640197152","market":"sh","top_or_hot":-1,"title":"依托成熟毒素平台 百利天恒BL-M05D1胃癌III期试验完成首例入组","media":"财中社","content":"<html><body><div>\n<p>　　6月4日，<span><a href=\"https://laohu8.com/S/688506\">百利天恒</a></span>（688506）发布公告，公司自主研发的创新生物药注射用BL-M05D1（Claudin18.2ADC）用于在既往经一线治疗的Claudin18.2阳性晚期胃癌或胃食管结合部腺癌的III期临床试验已完成首例受试者入组。</p><p>　　注射用BL-M05D1是与iza-bren共享同一“连接子+毒素”平台的ADC药物，目前正在国内外开展3项临床试验，其中包括1个III期、1个Ib期及1个Ia期临床试验，适应症为局部晚期实体瘤。</p><p>　　2026年一季度，<span href=\"http://quote.eastmoney.com/unify/r/116.02615\" target=\"_blank\" web=\"1\"><a href=\"https://laohu8.com/S/02615\">百利天恒</a></span>实现收入9459万元，归母净利润-7.75亿元。</p><p>（文章来源：财中社）</p> </div></body></html>","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>依托成熟毒素平台 百利天恒BL-M05D1胃癌III期试验完成首例入组</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n依托成熟毒素平台 百利天恒BL-M05D1胃癌III期试验完成首例入组\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<p>　　6月4日，<span><a href=\"https://laohu8.com/S/688506\">百利天恒</a></span>（688506）发布公告，公司自主研发的创新生物药注射用BL-M05D1（Claudin18.2ADC）用于在既往经一线治疗的Claudin18.2阳性晚期胃癌或胃食管结合部腺癌的III期临床试验已完成首例受试者入组。</p><p>　　注射用BL-M05D1是与iza-bren共享同一“连接子+毒素”平台的ADC药物，目前正在国内外开展3项临床试验，其中包括1个III期、1个Ib期及1个Ia期临床试验，适应症为局部晚期实体瘤。</p><p>　　2026年一季度，<span href=\"http://quote.eastmoney.com/unify/r/116.02615\" target=\"_blank\" web=\"1\"><a href=\"https://laohu8.com/S/02615\">百利天恒</a></span>实现收入9459万元，归母净利润-7.75亿元。</p><p>（文章来源：财中社）</p> </div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://finance.eastmoney.com/a/202606043760581427.html\">财中社</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4134","symbol_name":"信息科技咨询与其它服务","start_time":0,"source_url":"http://finance.eastmoney.com/a/202606043760581427.html","article_id":"2640197152","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640197152","pubTimestamp":1780573920,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"6月4日，百利天恒（688506）发布公告，公司自主研发的创新生物药注射用BL-M05D1（Claudin18.2ADC）用于在既往经一线治疗的Claudin18.2阳性晚期胃癌或胃食管结合部腺癌的III期临床试验已完成首例受试者入组。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"91194":"临工重机股份有限公司（临时代码）","688506":"百利天恒","BK4134":"信息科技咨询与其它服务","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","III":"信息服务","BK0239":"医药制造","02615":"百利天恒","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","BL":"Blackline Inc.","BK4023":"应用软件"},"translate_title":"Relying on a mature toxin platform, Baili Tianheng BL-M05D1 gastric cancer phase III trial completed the first case enrollment","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"91194":1.5,"688506":1.5,"02615":1.5,"BL":1.5,"III":1.5},"content_text":"6月4日，百利天恒（688506）发布公告，公司自主研发的创新生物药注射用BL-M05D1（Claudin18.2ADC）用于在既往经一线治疗的Claudin18.2阳性晚期胃癌或胃食管结合部腺癌的III期临床试验已完成首例受试者入组。　　注射用BL-M05D1是与iza-bren共享同一“连接子+毒素”平台的ADC药物，目前正在国内外开展3项临床试验，其中包括1个III期、1个Ib期及1个Ia期临床试验，适应症为局部晚期实体瘤。　　2026年一季度，百利天恒实现收入9459万元，归母净利润-7.75亿元。（文章来源：财中社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640197152","isCrawlerRequest":true}

依托成熟毒素平台 百利天恒BL-M05D1胃癌III期试验完成首例入组

精彩评论

依托成熟毒素平台百利天恒BL-M05D1胃癌III期试验完成首例入组